Cargando…
Immunotherapy – 2067. FEL d 1 peptide antigen desensitization safety and efficacy in a double-blind, placebo-controlled environmental exposure chamber study
Autores principales: | Hafner, Roderick Peter, Patel, Piyush, Salapatek, Annemarie, Laidler, Paul, Larché, Mark, Patel, Deepen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
World Allergy Organization
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643727/ http://dx.doi.org/10.1186/1939-4551-6-S1-P150 |
Ejemplares similares
-
Immunotherapy – 2080. Fel d 1 derived peptide antigen desensitization results in a persistent treatment effect on symptoms of cat allergy 1 year after 4 doses
por: Hafner, Roderick Peter, et al.
Publicado: (2013) -
Mechanisims of asthma and allergic disease – 1085. Safety and tolerability of escalating doses of house dust mite peptide antigen desensitisation
por: Hafner, Roderick Peter, et al.
Publicado: (2013) -
Two year persistent treatment effect in reducing nasal symptoms of cat allergy after 4 doses of Cat-PAD, the first in a new class of synthetic peptide immuno-regulatory epitopes
por: Hafner, Roderick, et al.
Publicado: (2013) -
COLLABORATION AGREEMENT KE2067/GS
por: THE EUROPEAN ORGANIZATION FOR NUCLEAR RESEARCH, CERN, et al.
Publicado: (2012) -
Clocks Generation PS/RF-LL 2067/2
por: Blas, F, et al.
Publicado: (1995)